Here’s a groundbreaking development that could change the game for millions: The US FDA has just approved the first oral weight loss drug designed to prevent heart attacks and strokes, and it’s already being used for diabetes management in India. But here’s where it gets controversial—while Rybelsus (oral semaglutide) has shown remarkable benefits, its side effects and long-term implications are sparking debates among experts. Let’s dive in.
Rybelsus, initially cleared in 2019 and introduced in India in 2022 for diabetes management, has now been FDA-approved for a dual purpose: managing blood sugar and reducing cardiovascular risks. This makes it a unique player in the pharmaceutical world, as it’s the first oral drug to tackle both weight loss and heart health simultaneously. Semaglutide, the active ingredient, belongs to a class called GLP-1 RAs (glucagon-like peptide-1 receptor agonists). In simpler terms, it mimics a hormone released in the gut after eating, signaling the body to produce more insulin and reduce blood sugar. But that’s not all—in higher doses, it interacts with the brain to suppress appetite, leading to weight loss.
And this is the part most people miss: The FDA’s expanded approval is based on the SOUL trial, which revealed that Rybelsus can reduce cardiovascular risks by nearly 14% in patients with Type 2 diabetes. The study, published in the New England Journal of Medicine, tracked 9,650 high-risk adults over four years. Participants taking a daily 14 mg dose of Rybelsus saw a significant 14% reduction in major adverse cardiovascular events (MACE) compared to those on a placebo. Interestingly, these benefits were consistent across all patient subgroups, even those without prior cardiovascular issues.
While serious cardiac events were less frequent in the Rybelsus group (47.9% vs. 50.3% in the placebo group), gastrointestinal side effects like nausea and vomiting were slightly higher (5.0% vs. 4.4%). This raises a thought-provoking question: Is the trade-off between cardiovascular benefits and gastrointestinal discomfort worth it? Let us know your thoughts in the comments.
Dr. V Mohan, chairman of Dr. Mohan’s Diabetes Specialities Centre in Chennai, highlights the drug’s potential impact in India, where premature heart attacks and diabetes are rampant. “An oral drug that controls both blood sugar and weight could be a game-changer,” he says. Rybelsus not only lowers HbA1c levels (average blood sugar over three months) but also aids in weight reduction, addressing two major risk factors for heart disease.
But how does it protect the heart? Studies show that Rybelsus reduces inflammation, a key driver of cardiovascular issues. Inflammation damages blood vessels, leading to fatty deposits, oxidative stress, and endothelial dysfunction—all of which Rybelsus targets. Dr. M Sudhakar Rao, a cardiology consultant at Manipal Hospital in Bengaluru, adds, “Inflammation reduction is crucial in preventing major cardiovascular events. Rybelsus also lowers LDL cholesterol, reduces platelet stickiness, and has mild diuretic effects, benefiting those with high blood pressure and heart failure.”
Managing side effects is key to successful treatment. Dr. Mohan recommends starting with small doses and gradually increasing them to improve tolerance. He also advises taking Rybelsus on an empty stomach with 50-100 ml of water and avoiding food or other medications for 30 minutes afterward. “This ensures optimal absorption and is a convenient alternative to weekly injectables,” he explains.
Here’s the million-dollar question: As Rybelsus gains traction, will it revolutionize diabetes and cardiovascular care, or will its side effects limit its widespread adoption? Share your opinions below—we’d love to hear your take on this groundbreaking yet controversial drug.
